Pregnancy and lactation | Mono-Embolex

Pregnancy and lactation

There is a lot of experience regarding the use of low molecular weight heparins in pregnancy. In the first 12 weeks of pregnancy, no harmful effect on the embryo could be observed when using Mono-Embolex®. This finding is based on approximately 2,800 observed pregnancies under Certoparin therapy.

Mono-Embolex® does not appear to pose any risk to the unborn child in the further course of the pregnancy.In comparison, the risk of osteoporosis in pregnant women is lower when using a low-molecular-weight heparin than when using a standard heparin. Before surgery or at the beginning of birth, the Mono-Embolex® therapy should be stopped or at least interrupted if possible. Whether Mono-Embolex® passes into breast milk during lactation has not yet been investigated.

However, the use of other low-molecular-weight heparins during lactation has not been shown to cause clinical symptoms in breastfed infants. Therefore, the administration of a heparin, even a low-molecular-weight heparin, may be continued while breastfeeding. Please discuss the injection of Mono-Embolex® during pregnancy and lactation with your treating physician.

Contraindications

Mono-Embolex® should not be used if an intolerance to certoparin and/or heparin or other components of Mono-Emblex® is known. Another contraindication, i.e. a factor that speaks against this therapeutic measure, is a previous heparin-induced thrombocytopenia of type II, i.e. a drop in platelets caused by antibodies.

Current or recent bleeding, fresh injuries and known gastrointestinal ulcers also speak against the use of Mono-Embolex®. Mono-Embolex® must also not be used in the case of injuries or operations on the central nervous system, eye or ear. If a pregnant woman is threatened with miscarriage, the use of this low-molecular heparin should be avoided.

In addition, Mono-Embolex® should not be used directly before or after a lumbar puncture, as is the case with spinal anesthesia. Furthermore, there are situations where Mono-Embolex® should be prescribed with caution. These include severe impairment of kidney function with a creatinine clearance of less than 30 ml/min, a reduced platelet count (thrombocytopenia) or impaired platelet function, impaired liver or pancreatic function, and a history of stomach and/or intestinal ulcers. Mono-Embolex® should also be used with caution in the treatment of kidney stones and ureteral stones, when taking drugs that increase serum potassium levels, and when there is suspicion of a tumor disease inside the skull with a tendency to bleed.